✦ LIBER ✦

Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer

✍ Scribed by Amer K. Karam; Beth Y. Karlan

Book ID: 113962236
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 67 KB
Volume: 116
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2009.09.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Extreme drug resistance assay does not i

Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer

✍ Robert W. Holloway 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Extreme drug resistance assay results do

Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer

✍ Amer K. Karam; Jing Wang Chiang; Ewina Fung; Vladimir Nossov; Beth Y. Karlan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Should the extreme drug resistance assay

Should the extreme drug resistance assay fade into oblivion? Commentary on Karam, A.K., Chiang, J.W., Fung, E., Nossov, V. and Karlan, B.Y. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol. 2009;114:246–252

✍ Jens Einenkel; Patricia Wuttke; Katharina Horn 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Correlation between Extreme Drug Resista

Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer

✍ Gamal H. Eltabbakh; M.Steven Piver; Ronald E. Hempling; Fernando O. Recio; Shash 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Low drug resistance to both platinum and

Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer

✍ Koji Matsuo; Virginia K. Bond; Michele L. Eno; Dwight D. Im; Neil B. Rosenshein 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract The objective of this study was to evaluate the role of an __in vitro__ drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer. All patients with FIGO Stage IIIc and IV who received postoperative chemotherap

CON: Therapy for a Patient with Platinum

CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

✍ John Farley; Michael J. Birrer 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 342 KB